Form 4: Foghorn Therapeutics Director Acquires Stock Options

Director Michael Mendelsohn acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, at a price of $5.52 per share.

Summary

• On June 26, 2024, Michael Mendelsohn, a director of Foghorn Therapeutics Inc., acquired 16,000 stock options.
• The options were granted at an exercise price of $5.52 per share.
• The options become exercisable on June 26, 2025, and expire on June 25, 2034.
• This transaction was reported on a Form 4 filing with the SEC.
• Michael LaCascia, acting as Attorney-in-Fact for Michael Mendelsohn, signed the report on June 28, 2024.
• Mendelsohn has granted limited power of attorney to Kristian Humer, Michael LaCascia and Tara Maduri to prepare and execute SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, and does not inherently convey positive or negative sentiment.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry.
• The terms of the options, such as the exercise price and vesting schedule, are generally aligned with industry standards for incentivizing long-term performance.

Key Dates